Literature DB >> 26087110

A sustained intravitreal drug delivery system with remote real time monitoring capability.

Huiyuan Hou1, Alejandra Nieto2, Akram Belghith1, Kaihui Nan1, Yangyang Li2, William R Freeman1, Michael J Sailor2, Lingyun Cheng3.   

Abstract

Many chorioretinal diseases are chronic and need sustained drug delivery systems to keep therapeutic drug level at the disease site. Many intravitreal drug delivery systems under developing do not have mechanism incorporated for a non-invasive monitoring of drug release. The current study prepared rugate porous silicon (pSi) particles by electrochemical etching with the current frequency (K value) of 2.17 and 2.45. Two model drugs (rapamycin and dexamethasone) and two drug-loading strategies were tested for the feasibility to monitor drug release from the pSi particles through a color fundus camera. The pSi particles (k=2.45) with infiltration loading of rapamycin demonstrated progressively more violet color reflection which was negatively associated with the rapamycin released into the vitreous (r=-0.4, p<0.001, pairwise). In contrast, pSi with K value of 2.17 demonstrated progressive color change toward green and a weak association between rapamycin released into vitreous and green color abundance was identified (r=-0.23, p=0.002, pairwise). Dexamethasone was covalently loaded on to the fully oxidized pSi particles that appeared in vitreous as yellow color and fading over time. The yellow color decrease over time was strongly associated with the dexamethasone detected from the vitreous samples (r=0.7, p<0.0001, pairwise). These results suggest that engineered porous silicon particles may be used as a self-reporting drug delivery system for a non-invasive real time remote monitoring. STATEMENT OF SIGNIFICANCE: The current study, for the first time, demonstrated proof of concept that engineered porous silicon photonic crystal may deliver therapeutics in a controlled fashion while at the same time might offer a noninvasive remote monitoring of its payload release in a living eye. Porous silicon photonic crystal changes color which is in association with its payload release into vitreous. With further optimization, the color change may be harnessed to inform eye care professionals of real time drug concentration in the eye and allow them to make informed decision to re-dose the patients.
Copyright © 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dexamethasone; Drug release monitoring; Intravitreal drug delivery; Porous silicon; Rapamycin

Mesh:

Substances:

Year:  2015        PMID: 26087110      PMCID: PMC4560601          DOI: 10.1016/j.actbio.2015.06.012

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  33 in total

1.  Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle.

Authors:  L Cheng; E Anglin; F Cunin; D Kim; M J Sailor; I Falkenstein; A Tammewar; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-05       Impact factor: 4.638

2.  A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.

Authors:  Huiyuan Hou; Kristyn Huffman; Sandy Rios; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-04       Impact factor: 4.799

3.  Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles.

Authors:  Elizabeth C Wu; Jennifer S Andrew; Lingyun Cheng; William R Freeman; Lindsey Pearson; Michael J Sailor
Journal:  Biomaterials       Date:  2010-11-30       Impact factor: 12.479

4.  Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.

Authors:  Shelley Day; Kofi Acquah; Prithvi Mruthyunjaya; Daniel S Grossman; Paul P Lee; Frank A Sloan
Journal:  Am J Ophthalmol       Date:  2011-06-12       Impact factor: 5.258

5.  Design and characterization of biofunctional magnetic porous silicon flakes.

Authors:  A Muñoz Noval; R García; D Ruiz Casas; D Losada Bayo; V Sánchez Vaquero; V Torres Costa; R J Martín Palma; M A García; J P García Ruiz; J J Serrano Olmedo; J F Muñoz Negrete; F del Pozo Guerrero; M Manso Silván
Journal:  Acta Biomater       Date:  2012-12-11       Impact factor: 8.947

6.  Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.

Authors:  Chengyun Wang; Huiyuan Hou; Kaihui Nan; Michael J Sailor; William R Freeman; Lingyun Cheng
Journal:  Exp Eye Res       Date:  2014-11-05       Impact factor: 3.467

7.  Multilayer reflectors in animals using green and gold beetles as contrasting examples

Authors: 
Journal:  J Exp Biol       Date:  1998-05       Impact factor: 3.312

Review 8.  The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies.

Authors:  Rocío Herrero-Vanrell; Irene Bravo-Osuna; Vanessa Andrés-Guerrero; Marta Vicario-de-la-Torre; Irene Teresa Molina-Martínez
Journal:  Prog Retin Eye Res       Date:  2014-05-10       Impact factor: 21.198

9.  Isopropanol protein precipitation for the analysis of plasma free metanephrines by liquid chromatography-tandem mass spectrometry.

Authors:  Luke C Marney; Thomas J Laha; Geoffrey S Baird; Petrie M Rainey; Andrew N Hoofnagle
Journal:  Clin Chem       Date:  2008-08-07       Impact factor: 8.327

Review 10.  Intravitreal devices for the treatment of vitreous inflammation.

Authors:  John B Christoforidis; Susie Chang; Angela Jiang; Jillian Wang; Colleen M Cebulla
Journal:  Mediators Inflamm       Date:  2012-09-05       Impact factor: 4.711

View more
  4 in total

1.  Self-Reporting Photoluminescent Porous Silicon Microparticles for Drug Delivery.

Authors:  Joanna Wang; Tushar Kumeria; Maria Teresa Bezem; Jian Wang; Michael J Sailor
Journal:  ACS Appl Mater Interfaces       Date:  2018-01-16       Impact factor: 9.229

Review 2.  A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology.

Authors:  Nasiq Hasan; Rohan Chawla; Nawazish Shaikh; Sindhuja Kandasamy; Shorya Vardhan Azad; M Dheepak Sundar
Journal:  Ther Adv Ophthalmol       Date:  2022-05-18

3.  Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits' eyes.

Authors:  Mayara Rodrigues Brandão De Paiva; Nayara Almeida Lage; Maria Carolina Andrade Guerra; Marcos Paulo Gomes Mol; Marcela Coelho Silva Ribeiro; Gustavo De Oliveira Fulgêncio; Dawidson A Gomes; Isabela Da Costa César; Sílvia Ligório Fialho; Armando Silva-Cunha
Journal:  Doc Ophthalmol       Date:  2018-11-19       Impact factor: 2.379

4.  In Vitro and In Vivo Sustained Zero-Order Delivery of Rapamycin (Sirolimus) From a Biodegradable Intraocular Device.

Authors:  Kevin D Lance; Samuel D Good; Thaís S Mendes; Mynna Ishikiriyama; Patrick Chew; Laurel S Estes; Kazuhito Yamada; Sri Mudumba; Robert B Bhisitkul; Tejal A Desai
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-11       Impact factor: 4.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.